Literature DB >> 19106779

Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients.

Jennifer R King1, Edward P Acosta, Ram Yogev, Andrew Wiznia, Joyce Kraimer, Bobbie Graham, Vincent Carey, Paula Britto, Patrick Jean-Philippe, John Moye, Douglas Watson.   

Abstract

The pharmacokinetics of lopinavir/ritonavir (LPV/RTV) 300 mg/m twice daily and efavirenz (EFV) 350 mg/m once daily were evaluated in HIV-infected children. The minimum concentrations for LPV contained values above the target range, and the estimated minimum concentrations for EFV contained values below the range. Our data support the current LPV/RTV dose, but EFV 350 mg/m may not be sufficient.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19106779      PMCID： PMC2755569          DOI： 10.1097/INF.0b013e3181861d8b

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  9 in total

1.  Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz.

Authors:  Eric Dailly; Clotilde Allavena; François Raffi; Pascale Jolliet
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

2.  High prevalence of subtherapeutic plasma concentrations of efavirenz in children.

Authors:  Yuan Ren; James J C Nuttall; Claire Egbers; Brian S Eley; Tammy M Meyers; Peter J Smith; Gary Maartens; Helen M McIlleron
Journal:  J Acquir Immune Defic Syndr       Date:  2007-06-01       Impact factor: 3.731

Review 3.  Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.

Authors:  Imke H Bartelink; Carin M A Rademaker; Alfred F A M Schobben; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines.

Authors:  Nils von Hentig; C Koenigs; S Elanjikal; R Linde; D Dunsch; W Kreuz; M B Funk
Journal:  Eur J Med Res       Date:  2006-09-29       Impact factor: 2.175

5.  Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.

Authors:  Alina S Bergshoeff; Pieter L Fraaij; Jennifer Ndagijimana; Gwenda Verweel; Nico G Hartwig; Tim Niehues; Ronald De Groot; David M Burger
Journal:  J Acquir Immune Defic Syndr       Date:  2005-05-01       Impact factor: 3.731

6.  Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.

Authors:  S E Starr; C V Fletcher; S A Spector; F H Yong; T Fenton; R C Brundage; D Manion; N Ruiz; M Gersten; M Becker; J McNamara; L M Mofenson; L Purdue; S Siminski; B Graham; D M Kornhauser; W Fiske; C Vincent; H W Lischner; W M Dankner; P M Flynn
Journal:  N Engl J Med       Date:  1999-12-16       Impact factor: 91.245

7.  Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.

Authors:  Ann Hsu; Jeffrey Isaacson; Scott Brun; Barry Bernstein; Wayne Lam; Richard Bertz; Cheryl Foit; Karen Rynkiewicz; Bruce Richards; Martin King; Richard Rode; Dale J Kempf; G Richard Granneman; Eugene Sun
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

8.  Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.

Authors:  Xavier Sáez-Llorens; Avyi Violari; Carl O Deetz; Richard A Rode; Perry Gomez; Edward Handelsman; Stephen Pelton; Octavio Ramilo; Pedro Cahn; Ellen Chadwick; Upton Allen; Stephen Arpadi; Maria Mercedes Castrejón; Renee S Heuser; Dale J Kempf; Richard J Bertz; Ann F Hsu; Barry Bernstein; Cheryl L Renz; Eugene Sun
Journal:  Pediatr Infect Dis J       Date:  2003-03       Impact factor: 2.129

9.  Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography.

Authors:  Michele L Turner; Kedria Reed-Walker; Jennifer R King; Edward P Acosta
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-02-05       Impact factor: 3.205
  9 in total
  4 in total

Review 1.  Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.

Authors:  Michael N Neely; Natella Y Rakhmanina
Journal:  Clin Pharmacokinet       Date:  2011-03       Impact factor: 6.447

Review 2.  Post-HAART outcomes in pediatric populations: comparison of resource-limited and developed countries.

Authors:  Elizabeth Peacock-Villada; Barbra A Richardson; Grace C John-Stewart
Journal:  Pediatrics       Date:  2011-01-24       Impact factor: 7.124

Review 3.  Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges.

Authors:  B Ryan Phelps; Natella Rakhmanina
Journal:  Paediatr Drugs       Date:  2011-06-01       Impact factor: 3.022

4.  Pharmacotherapy of pediatric and adolescent HIV infection.

Authors:  Susan J Schuval
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.